Human BCL10 knockout HeLa cell lysate
Be the first to review this product! Submit a review
|
(0 Publication)
BCL10 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 1.
View Alternative Names
AI132454, B-cell CLL/lymphoma 10, B-cell leukemia/lymphoma 10, B-cell lymphoma/leukemia 10, BCL10_HUMAN, C81403, CARD containing molecule enhancing NF-kB, CARD-containing apoptotic signaling protein, CARD-containing molecule enhancing NF-kappa-B, CARD-containing proapoptotic protein, CARD-like apoptotic protein, CARMEN, CED-3/ICH-1 prodomain homologous E10-like regulator, CIPER, CLAP, Cellular homolog of vCARMEN, Cellular-E10, Mammalian CARD-containing adapter molecule E10, R-RCD1, c-E10, cCARMEN, caspase-recruiting domain-containing protein, hCLAP, mE 10
- Sanger seq
Unknown
Sanger Sequencing - Human BCL10 knockout HeLa cell lysate (AB257144)
Homozygous : 1 bp insertion in exon 1
- WB
Lab
Western blot - Human BCL10 knockout HeLa cell lysate (AB257144)
Lane 1 : Wild-type HeLa cell lysate (20 μg)
Lane 2 : BCL10 knockout HeLa cell lysate (20 μg)
Lane 3 : Ramos cell lysate (20 μg)
Lane 4 : A549 cell lysate (20 μg)
Lanes 1-4 : Merged signal (red and green). Green - ab33905 observed at 32 kDa. Red - loading control, ab7291 observed at 52 kDa.
ab33905 Anti-Bcl10 antibody [EP606Y] was shown to specifically react with Bcl10 in wild-type HeLa cells. Loss of signal was observed when knockout cell line ab261797 (knockout cell lysate ab257144) was used. Wild-type and Bcl10 knockout samples were subjected to SDS-PAGE. ab33905 and Anti-alpha Tubulin antibody [DM1A] - Loading Control (ab7291) were incubated overnight at 4°C at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1 in 10000 dilution for 1 hour at room temperature before imaging.
All lanes:
Western blot - Anti-Bcl10 antibody [EP606Y] (<a href='/en-us/products/primary-antibodies/bcl10-antibody-ep606y-ab33905'>ab33905</a>) at 1/1000 dilution
Lane 1:
Wild-type HeLa cell lysate at 20 µg
Lane 2:
Western blot - Human BCL10 knockout HeLa cell lysate (ab257144)
Lane 3:
Ramos cell lysate at 20 µg
Lane 4:
A549 cell lysate at 20 µg
Predicted band size: 26 kDa
Observed band size: 32 kDa
false
- WB
Lab
Western blot - Human BCL10 knockout HeLa cell lysate (AB257144)
Lane 1 : Wild-type HeLa cell lysate (20 μg)
Lane 2 : BCL10 knockout HeLa cell lysate (20 μg)
Lane 3 : Ramos cell lysate (20 μg)
Lane 4 : A549 cell lysate (20 μg)
Lanes 1-4 : Merged signal (red and green). Green - ab150380 observed at 32 kDa. Red - loading control, ab7291 observed at 52 kDa.
ab150380 Anti-Bcl10 antibody [EPR8587] was shown to specifically react with Bcl10 in wild-type HeLa cells. Loss of signal was observed when knockout cell line ab261797 (knockout cell lysate ab257144) was used. Wild-type and Bcl10 knockout samples were subjected to SDS-PAGE. ab150380 and Anti-alpha Tubulin antibody [DM1A] - Loading Control (ab7291) were incubated overnight at 4°C at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1 in 10000 dilution for 1 hour at room temperature before imaging.
All lanes:
Western blot - Anti-Bcl10 antibody [EPR8587] (<a href='/en-us/products/primary-antibodies/bcl10-antibody-epr8587-ab150380'>ab150380</a>) at 1/1000 dilution
Lane 1:
Wild-type HeLa cell lysate at 20 µg
Lane 2:
Western blot - Human BCL10 knockout HeLa cell line (<a href='/en-us/products/cell-lines/human-bcl10-knockout-hela-cell-line-ab261797'>ab261797</a>)
Lane 2:
Western blot - Human BCL10 knockout HeLa cell lysate (ab257144)
Lane 3:
Ramos cell lysate at 20 µg
Lane 4:
A549 cell lysate at 20 µg
Predicted band size: 26 kDa
Observed band size: 32 kDa
false
Reactivity data
Product details
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.
What's included?
Properties and storage information
Gene name
Gene editing type
Gene editing method
Knockout validation
Zygosity
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
Bcl10 activates downstream signaling pathways that are critical for immune cell functioning and survival. It forms part of the CARD-BCL10-MALT1 (CBM) complex which is important for the activation of the NF-kB pathway. This complex formation is essential for lymphocyte activation and proliferation. Bcl10 interactions within this complex influence cellular responses to various stimuli helping organisms to mount appropriate immune responses.
Pathways
Bcl10 serves as an integral component in the NF-kB and TCR signaling pathways. It functions alongside proteins such as MALT1 and CARD9 in these pathways. The proper functioning of Bcl10 in these pathways ensures accurate transcriptional regulation necessary for immune responses. Misregulation in these pathways can lead to immune disorders and aberrant cell behavior linking Bcl10 to further biological implications.
Quality control
STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
Biosafety level
EU: 2 US: 2
Adherent/suspension
Adherent
Gender
Female
Complementary Products
![Immunocytochemistry/ Immunofluorescence - Anti-Bcl10 antibody [EP606Y] (AB33905)](https://content.abcam.com/products/images/bcl10-antibody-ep606y-ab33905--immunocytochemistry-immunofluorescence-img70938.jpg)
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com